Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus

Mori, Katsuhito; Emoto, Masanori; Araki, Tsuyoshi; Yokoyama, Hisayo; Lee, Eiko; Teramura, Megumi; Koyama, Hidenori; Shoji, Tetsuo; Inaba, Masaaki; Nishizawà, Yoshiki

doi:10.1016/j.metabol.2008.04.019

Cited by 72 publications

(60 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, in both models for comparative effects of metformin vs. pioglitazone, pioglitazone was superior to metformin in terms of lowering the serum fetuin-A in men; however, a similar effect was not seen with regard to the women. Similar to our findings, Mori et al in their preliminary report concluded that from the three groups of Insulin-sensitizing therapy (pioglitazone, metformin and aerobic exercise) only pioglitazone can significantly decrease fetuin-A [29]. Recently, Gateva et al showed that metformin treatment in PCOS (polycystic ovary syndrome) patients could not significantly reduce the levels of fetuin-A [30].…”

Section: Discussionsupporting

confidence: 90%

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Esteghamati

Afarideh

Feyzi

et al. 2015

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Esteghamati

Afarideh

Feyzi

et al. 2015

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

“…Lifestyle modifications remain the easiest step to reduce the risk of obesity and hepatic steatosis. Medications such as valsartan in adolescents with T1D [68] or pioglitazone with and without fenofibrate in T2D [5, 69, 70, 71] were observed to reduce fetuin A levels [72], with variable effects of metformin [69, 70, 72]. Under certain living and dietary habits, therapeutic interventions targeting fetuin A may also be useful in T1D.…”

Section: Discussionmentioning

confidence: 99%

Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes

et al. 2017

View full text Add to dashboard Cite

Background and Aim: The hepatokine fetuin A is upregulated in the metabolic syndrome and in type 2 diabetes (T2D), while its role in adolescent type 1 diabetes (T1D) is unclear. We assessed the relationship between circulating fetuin A levels and metabolic control, comorbidities, and complications in adolescent T1D patients. Methods: We studied the relationship between serum fetuin A and clinical diabetes-related data from the DPV registry (Diabetes-Patienten-Verlaufsdokumentation) in 172 adolescent T1D patients with early-onset (<5 years) long-standing (>10 years) T1D. Fetuin A levels were further compared between adolescent T1D and T2D patients. Results: Serum fetuin A levels in T1D patients (mean 0.267 ± 0.043 g/L) did not correlate with age, diabetes duration, gender, body mass index (BMI), glycated hemoglobin, serum lipid levels, blood pressure, celiac or thyroid disease, nephropathy, or retinopathy. An association of fetuin A levels with insulin requirements was only evident within the subgroup of overweight T1D patients (r_s = 0.439, p = 0.028, n = 25, BMI >90th percentile), disappearing after adjustment for multiple testing. Adolescent T1D patients showed distinctly lower fetuin A levels than patients with T2D (p ≤ 0.001). Conclusion: Overall, we did not observe a clinically relevant association of fetuin A levels with surrogate parameters for insulin sensitivity in our juvenile T1D cohort. A correlation with insulin requirements was detectable in overweight patients only. We hypothesize that multiple factors, such as obesity, puberty, inadequate metabolic control, and hepatic steatosis, have to add up before a clinically relevant effect of fetuin A on insulin sensitivity becomes evident.

show abstract

“…One study shows that Fetuin A significantly decreased after 6 months of pioglitazone treatment in patients with type 2 diabetes while there were no changes in serum fetuin-A after intervention in either the metformin or aerobic exercise [37]. Authors hypothesize that pioglitazone could partially ameliorate insulin resistance via modulating fetuin A levels.…”

Section: Discussionmentioning

confidence: 99%

MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment

2013

View full text Add to dashboard Cite

show abstract

Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus

Cited by 72 publications

References 20 publications

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes

MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment

Contact Info

Product

Resources

About